Sign in

You're signed outSign in or to get full access.

Marta Nazarovets Zaremba

Vice President at JPMorgan Chase & Co.

Marta Nazarovets Zaremba is a Vice President at JPMorgan Securities LLC, having joined the firm in 2025 where she serves as an analyst with a specialization in financial markets and equity research. She provides coverage of a diverse roster of publicly traded companies, though specific company names and detailed performance track records such as success rates or return metrics are not publicly disclosed. Marta began her professional journey after graduating in 2017, advancing quickly to her current leadership role at JPMorgan Securities LLC. Her professional credentials and securities licenses have not been publicly reported, nor are there publicly referenced industry rankings or notable analyst awards.

Marta Nazarovets Zaremba's questions to BRUKER (BRKR) leadership

Question · Q2 2025

Marta Nazarovets Zaremba, on behalf of Rachel Vatnsdal, sought clarification on the tariff assumptions embedded in the updated guidance, specifically asking what rate is being modeled for Swiss imports and for broader details on other regions.

Answer

Chairman, CEO & President Frank Laukien stated that the guidance models a 15% tariff for Switzerland, in line with the EU. He noted that a worst-case 39% rate is not expected to materialize, as the company believes the final rate will be lower and, if necessary, it can shift production for the US market from Switzerland to its factories in Germany or France to mitigate the impact.

Ask follow-up questions

Fintool

Fintool can predict BRUKER logo BRKR's earnings beat/miss a week before the call

Marta Nazarovets Zaremba's questions to Seer (SEER) leadership

Question · Q4 2024

Marta Nazarovets asked about the impact of recent NIH funding uncertainty on research customers and whether the company was seeing increased hesitation or changes in academic customer trends in early 2025. She also inquired about the publication pipeline for 2025 and any large-scale projects on the horizon.

Answer

Executive Omid Farokhzad noted that government and academic customers represented about 30% of 2024 revenue and that the 2025 guidance fully incorporates the cautious mindset stemming from NIH funding uncertainty. Executive David Horn added that early Q1 trends show this uncertainty is causing some project delays. Regarding publications, Omid Farokhzad expressed strong optimism, expecting the pace to continue accelerating in 2025, driven by the STAC program and highlighting recent presentations at the HUPO conference and a newly accepted nature-level paper from a customer.

Ask follow-up questions

Fintool

Fintool can predict Seer logo SEER's earnings beat/miss a week before the call